Ethic Inc. Has $5.54 Million Stock Holdings in Zoetis Inc. $ZTS

Ethic Inc. decreased its position in Zoetis Inc. (NYSE:ZTS) by 28.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 37,851 shares of the company’s stock after selling 15,402 shares during the quarter. Ethic Inc.’s holdings in Zoetis were worth $5,538,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Institute for Wealth Management LLC. boosted its holdings in Zoetis by 6.8% during the third quarter. Institute for Wealth Management LLC. now owns 1,880 shares of the company’s stock worth $275,000 after purchasing an additional 119 shares during the last quarter. Kavar Capital Partners Group LLC lifted its position in Zoetis by 26.0% during the 3rd quarter. Kavar Capital Partners Group LLC now owns 15,494 shares of the company’s stock worth $2,267,000 after buying an additional 3,200 shares in the last quarter. Three Seasons Wealth LLC boosted its stake in shares of Zoetis by 11.2% during the 3rd quarter. Three Seasons Wealth LLC now owns 8,943 shares of the company’s stock worth $1,309,000 after buying an additional 902 shares during the last quarter. Regatta Capital Group LLC grew its holdings in shares of Zoetis by 4.5% in the 3rd quarter. Regatta Capital Group LLC now owns 12,923 shares of the company’s stock valued at $1,891,000 after acquiring an additional 558 shares in the last quarter. Finally, Fire Capital Management LLC increased its position in shares of Zoetis by 1.5% in the third quarter. Fire Capital Management LLC now owns 11,774 shares of the company’s stock valued at $1,723,000 after acquiring an additional 177 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 0.3%

ZTS stock opened at $125.90 on Tuesday. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.40. The stock has a market cap of $55.48 billion, a price-to-earnings ratio of 21.19, a price-to-earnings-growth ratio of 2.74 and a beta of 0.97. The company has a fifty day moving average price of $126.66 and a two-hundred day moving average price of $142.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s revenue was up .5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZTS. JPMorgan Chase & Co. reduced their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. UBS Group cut their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, December 23rd. Stifel Nicolaus dropped their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Finally, BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.